Sequential Induction of MHC Antigens on Autochthonous Cells of Ileum Affected by Crohn's Disease
Overview
Affiliations
Changes were examined in the expression of Class I and II major histocompatibility complex (MHC) antigens by autochthonous cells of the terminal ileum affected by Crohn's disease. The study was based on the analysis of transmural specimens from terminal ileum segments obtained in the course of ileocolectomy for colon cancer and Crohn's disease. Serial sections were immunostained using monoclonal antibodies directed against monomorphic determinants of HLA-A,B,C, DR, DP, DQ, and the invariant chain (Ii) associated with Class II molecules. Compared with the normal state, the only change in Class I antigen expression occurring in Crohn's disease was the induction of HLA-A,B,C antigens in lymphatic endothelium. Changes in Class II antigen expression were more substantial. Enhancement of HLA-DR expression was found in enterocytes; DR induction was observed in glial cells of the visceral nervous plexus and in venular and venous endothelium. HLA-DP and DQ antigens were induced in enterocytes, glial cells, and capillary and venular endothelium, although this induction was restricted to areas of moderate or high inflammatory activity. The tissue distribution of Ii closely resembled that of HLA-DR, although this association was not strict: on the one hand, arterial endothelium contained low amounts of Ii in the absence of DR antigens; on the other hand, glial cells expressed Class II molecules in the absence of Ii. The extent of local enhancement/induction of MHC antigens was positively correlated with the local density of the cellular infiltrate. These data suggest that altered MHC antigen expression by autochthonous structures might be mediated by factors released from the lymphohistiocytic infiltrate, which is itself attracted by an unknown signal. In conjunction with an unknown antigen, the enhanced expression of Class II antigens might trigger an autoaggressive immune response.
Cytokine induced inflammatory bowel disease model using organ-on-a-chip technology.
Tataru C, Livni M, Marean-Reardon C, Franco M, David M PLoS One. 2023; 18(12):e0289314.
PMID: 38091316 PMC: 10718466. DOI: 10.1371/journal.pone.0289314.
Guardians of the gut: influence of the enteric nervous system on the intestinal epithelial barrier.
Bubeck M, Becker C, Patankar J Front Med (Lausanne). 2023; 10:1228938.
PMID: 37692784 PMC: 10485265. DOI: 10.3389/fmed.2023.1228938.
Zanoletti L, Valdata A, Nehlsen K, Faris P, Casali C, Cacciatore R Front Cell Neurosci. 2023; 17:1170309.
PMID: 37153631 PMC: 10158601. DOI: 10.3389/fncel.2023.1170309.
Fecal S100A12 concentrations in cats with chronic enteropathies.
Zornow K, Slovak J, Lidbury J, Suchodolski J, Steiner J J Feline Med Surg. 2023; 25(3):1098612X231164273.
PMID: 36995216 PMC: 10812014. DOI: 10.1177/1098612X231164273.
Lopez-Gomez L, Szymaszkiewicz A, Zielinska M, Abalo R Molecules. 2022; 27(19).
PMID: 36235308 PMC: 9570628. DOI: 10.3390/molecules27196773.